MedTrace Logo

Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder

NCT04013464 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2019-07-09

No results posted yet for this study

Summary

The main objective was to compare the differences of PSG parameters and plasma melatonin levels before and after treatment with escitalopram for 8 weeks. Polysomnography (PSG) was detected over a night and blood samples were collected at 4 h intervals for 24 h from 13 male healthy controls and 13 male MDD patients before and after treatment with escitalopram for 8 weeks. The outcome measures included the levels of plasma melatonin, PSG parameters (include sleep architecture and power analysis) and scales.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Escitalopram

Escitalopram 10-20mg/d

Sponsors & Collaborators

  • National Institute on Drug Dependence, China

    collaborator OTHER

  • Peking University Sixth Hospital

    lead OTHER

Principal Investigators

  • Su-Xia Li, Doctor · National Institute on Drug Dependence, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-01
Primary Completion
2018-05-31
Completion
2018-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04013464 on ClinicalTrials.gov